Blade Therapeutics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$13.8M
- Investors
-
8
Blade Therapeutics General Information
Description
Developer of novel anti-fibrotic therapies intended to revolutionize the treatment of fibrotic disease. The company's therapies address various fibrotic diseases and their underlying pathophysiology to potentially reverse the damage to tissue, enabling patients to get cured of the disease without any side effects.
Contact Information
Website
www.blademed.comCorporate Office
- 50 Francisco Street
- Suite 450
- San Francisco, CA 94133
- United States
Corporate Office
- 50 Francisco Street
- Suite 450
- San Francisco, CA 94133
- United States
Blade Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC | 01-Jan-2023 | $13.8M | Completed | Generating Revenue | ||
| 10. PIPE | 08-Nov-2021 | Cancelled | Generating Revenue | |||
| 9. Reverse Merger | 08-Nov-2021 | Cancelled | Generating Revenue | |||
| 8. Later Stage VC (Series C) | 23-Oct-2019 | Completed | Generating Revenue | |||
| 7. Debt - General | 08-Mar-2019 | Completed | Clinical Trials - Phase 2 | |||
| 6. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 | ||||
| 5. Accelerator/Incubator | 30-Jun-2016 | Completed | Clinical Trials - Phase 2 | |||
| 4. Early Stage VC (Series B) | 08-Jun-2016 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series A) | 06-Jul-2015 | $6M | $6.5M | Completed | Clinical Trials - Phase 2 | |
| 2. Debt - General | 01-May-2015 | $500K | $500K | Completed | Clinical Trials - Phase 2 |
Blade Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-1 | ||||||||
| Series C | ||||||||
| Series B | 43,000,000 | $0.000100 | $0.07 | $1.05 | $1.05 | 1x | $1.05 | 39.26% |
| Series A | 6,500,000 | $0.000100 | $0.09 | $1 | $1 | 1x | $1 | 5.93% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Blade Therapeutics Comparisons
Industry
Financing
Details
Blade Therapeutics Competitors (55)
One of Blade Therapeutics’s 55 competitors is IFM Therapeutics, a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| IFM Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Galectin Therapeutics | Corporation | Norcross, GA | ||||
| Apeptico | Venture Capital-Backed | Vienna, Austria |
Blade Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Blade Therapeutics Patents
Blade Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020323923-A1 | Calpain inhibitors and uses thereof for treating neurological disorders | Inactive | 31-Jul-2019 | ||
| CA-3148822-A1 | Calpain inhibitors and uses thereof for treating neurological disorders | Pending | 31-Jul-2019 | ||
| EP-4003336-A1 | Calpain inhibitors and uses thereof for treating neurological disorders | Inactive | 31-Jul-2019 | ||
| EP-4003336-A4 | Calpain inhibitors and uses thereof for treating neurological disorders | Inactive | 31-Jul-2019 | ||
| US-20220257570-A1 | Calpain inhibitors and uses thereof for treating neurological disorders | Inactive | 31-Jul-2019 | A61K31/433 |
Blade Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Blade Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| OneVentures | Venture Capital | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Novartis Institutes for BioMedical Research | Corporation | Minority | ||
| MPM BioImpact | Venture Capital | Minority |
Blade Therapeutics Acquisitions (1)
Blade Therapeutics’s most recent deal was a Merger/Acquisition with ATXCo. The deal was made on 25-Sep-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ATXCo | 25-Sep-2019 | Merger/Acquisition | Biotechnology |
Blade Therapeutics FAQs
-
When was Blade Therapeutics founded?
Blade Therapeutics was founded in 2013.
-
Where is Blade Therapeutics headquartered?
Blade Therapeutics is headquartered in San Francisco, CA.
-
What is the size of Blade Therapeutics?
Blade Therapeutics has 31 total employees.
-
What industry is Blade Therapeutics in?
Blade Therapeutics’s primary industry is Drug Discovery.
-
Is Blade Therapeutics a private or public company?
Blade Therapeutics is a Private company.
-
What is Blade Therapeutics’s current revenue?
The current revenue for Blade Therapeutics is .
-
How much funding has Blade Therapeutics raised over time?
Blade Therapeutics has raised $127M.
-
Who are Blade Therapeutics’s investors?
OneVentures, Bristol-Myers Squibb, Deerfield Management, Novartis Institutes for BioMedical Research, and MPM BioImpact are 5 of 8 investors who have invested in Blade Therapeutics.
-
Who are Blade Therapeutics’s competitors?
IFM Therapeutics, NexImmune, TScan Therapeutics, Galectin Therapeutics, and Apeptico are some of the 55 competitors of Blade Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
